The collaborative newly published statement stressed the need to address gaps in care that may lead to high risk of stroke recurrence.
The director of the headache section at Cleveland Clinic detailed some of the emerging nonpharmacological preventive methods for migraine, as well as where research is headed following the explosion of CGRP-targeting therapies. [WATCH TIME: 6 minutes]
The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]
The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
Episode 29 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Allison Brashear MD, MBA, of University at Buffalo. [WATCH TIME: 5 minutes]
The head of Biogen’s MS and Immunology Department Unit detailed the potential of combination approaches to treat MS, including the reasons for diroximel fumarate in the newly initiated phase 2 FUSION study. [WATCH TIME: 3 minutes]
The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]
Caution is warranted for older patients with Duchenne muscular dystrophy who are receiving gene therapy, according to details of a patient death in a single patient trial.
Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]
As therapeutic development has advanced in Parkinson disease management, the introduction of on-demand options have extended ON time for patients and altered the paradigm of care.
The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]
Arun S. Varadhachary, MD, PhD shares insights into clinicians’ and patients’ experiences with medical therapy, comments on unmet needs for adult patients, and speculates about the future of SMA care.
The postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.
The chief executive at Encephalitis International talked about results from a recent survey conducted on the misconceptions of encephalitis recognition among emergency medical professionals. [WATCH TIME: 5 minutes]
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Psychosis is estimated to affect more than half of patients with Parkinson disease, and there is a growing need for improved management and therapeutic development.
Jason Freeman, MD, MBA, and Shankar Sadasivan, PhD, discuss the poster “Immunoglobulins in Primary Progressive and Relapsing-Remitting Multiple Sclerosis” presented at ACTRIMS 2023. Sponsored By Novartis.
The president of the American Academy of Sleep Medicine emphasized the need to prioritize sleep for children and the organization’s efforts to improve sleep health.
The pediatric headache specialist at NYU Langone provided an inside perspective on the effect that societal stigmas have on those with pediatric migraine and how to address those stigmas.
Mary Meskis, executive director of the Dravet Syndrome Foundation, provided a opportunities the organization is offering in honor of Dravet Syndrome Awareness Month.
Episode 21 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Michael Dobbs, MD, MHCM, of University of Texas at Rio Grand Valley. [WATCH TIME: 5 minutes]
The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]
The executive director of Banner Alzheimer’s Institute discussed the approval of aducanumab and the potential to address unmet needs and gaps in care for patients with Alzheimer disease.
A feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).